{"id":"W2059228450","doi":"10.1016/j.ejca.2014.04.008","title":"A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Rash; Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; KRAS; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Phases of clinical research; Progressive disease; Gastroenterology; Adverse effect; Cancer; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001760632,0.0001532068,0.0008676345,0.0002800547,0.0000510255,0.0000051289,0.0001963234,0.00002717523,0.0005743145],"category_scores_gemma":[0.0005133525,0.0001127586,0.00009065378,0.000274262,0.0000997577,0.0001007157,0.0000581709,0.0004822941,0.000006437266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001612713,"about_ca_system_score_gemma":0.0003443825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001270509,"about_ca_topic_score_gemma":0.000143787,"domain_scores_codex":[0.997498,0.0006401683,0.0008990812,0.0001694954,0.0005192895,0.0002739794],"domain_scores_gemma":[0.998363,0.0001668024,0.0005756763,0.0002591054,0.0004294844,0.0002059086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009816458,0.01047242,0.5450543,0.0002689835,0.0007977893,0.0008818222,0.009558098,0.0002166265,0.03101494,0.00002241463,0.002249971,0.3896462],"study_design_scores_gemma":[0.08602472,0.06266422,0.806223,0.002094672,0.001039792,0.0001004251,0.002440286,0.0005124639,0.0007970071,0.0000257199,0.03778415,0.0002935477],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888119,0.003201205,0.00006525897,0.0006012273,0.0002142167,0.0003887585,0.000004392371,0.0000073893,0.006705692],"genre_scores_gemma":[0.9960107,0.001179285,0.0003977784,0.000184323,0.0004310154,0.00001426674,7.586964e-7,0.00003611174,0.001745729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3893526,"threshold_uncertainty_score":0.6288341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03875342993914899,"score_gpt":0.396565932724892,"score_spread":0.3578125027857431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}